Immuneering Corporation (IMRX) Earnings Call Transcripts

Immuneering Corporation's Latest Earnings Call - June 1, 2026

Immuneering Corporation reported positive results for Q2 FY2026, highlighting significant progress in their Phase IIa study of atebimetinib for first-line pancreatic cancer. The company reported a median overall survival of 17.3 months, surpassing the standard of care benchmark of 8.5 months. No revenue or earnings figures were discussed, as the focus was on clinical trial data. Management provided guidance on the ongoing Phase III MAPKeeper 301 study, which is now recruiting, and outlined future milestones, including a Phase II lung cancer study expected in late 2027.

Reported metrics

Guidance from management

Management is optimistic about the ongoing recruitment for the Phase III MAPKeeper 301 study, with plans to dose the first patient in mid-2026. They anticipate a Phase II lung cancer study readout in late 2027.

What management said

5 Thank you. I want to thank everyone for joining our call today. And we would also like to thank all the patients and investigators involved in our ongoing studies, and we look forward to updating you on our further progress. Thank you, everyone.

What analysts pressed on

Analysts questioned the impact of new competitive treatments in the second-line setting on the Phase III study's control arm. There was also interest in the correlation between overall survival and other efficacy metrics like ORR and PFS.

Main topics on the call

• Phase IIa Study Results — The Phase IIa study of atebimetinib showed a median overall survival of 17.3 months in first-line pancreatic cancer patients, with favorable tolerability. 'Only 2 categories of treatment-related adverse events at the gra...
• Comparison to Standard of Care — The study's median overall survival of 17.3 months is well above the 8.5 months benchmark from the pivotal study of standard-of-care gemcitabine nab-paclitaxel. 'The curves stay well separated all the way out to our medi...
• Expanded Cohort Consistency — The expanded cohort of 55 patients maintained a median overall survival of 17.3 months, consistent with the original 34-patient cohort. 'The fact that overall survival is essentially the same as we increase the cohort by...
• Tolerability and Weight Stability — 84% of patients were weight stable or gained weight, which is significant given the association between weight loss and increased mortality in pancreatic cancer. 'This preservation of body mass may contribute to survival...

Read the full Immuneering Corporation transcript (June 1, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 10 Immuneering Corporation earnings call transcripts on record, spanning March 6, 2023 to June 1, 2026. Based on this history, Immuneering Corporation reports semi-annually. The most recent call on file is dated June 1, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

IMRX

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

10

First call

March 6, 2023

Most recent

June 1, 2026

Reporting cadence

semi-annually